Last reviewed · How we verify
Ribamidine (TARIBAVIRIN)
Ribamidine (generic name: TARIBAVIRIN) is a taribavirin drug. It is currently in Phase 3 development.
Ribamidine works by inhibiting viral replication, although the exact mechanism is unknown.
Ribamidine is a small molecule with no verified information on its mechanism of action. It has been studied in combination with other treatments for Chronic Hepatitis C, Hepatitis C, and Chronic Hepatitis C in clinical trials.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TARIBAVIRIN |
|---|---|
| Drug class | taribavirin |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Think of it like a copy machine. Viruses make copies of themselves to spread, and Ribamidine tries to stop that process. It's like jamming the copy machine so it can't make more copies.
Approved indications
Common side effects
Key clinical trials
- Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV) (PHASE2)
- Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive (PHASE3)
- Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C (PHASE2)
- Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ribamidine CI brief — competitive landscape report
- Ribamidine updates RSS · CI watch RSS
Frequently asked questions about Ribamidine
What is Ribamidine?
How does Ribamidine work?
What is the generic name of Ribamidine?
What drug class is Ribamidine in?
What development phase is Ribamidine in?
Related
- Drug class: All taribavirin drugs
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing